Quarterly report pursuant to Section 13 or 15(d)

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)

v3.24.3
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)
 9 Months Ended
Sep. 30, 2024
Payables and Accruals [Abstract]  
Schedule of Accounts Payable and Accrued Liabilities
The components of accrued expenses and other current liabilities are as follows:
September 30, 2024 (unaudited) December 31, 2023
Deferred income - ERC (1)
$ 10,140  $ 10,140 
Goods received not invoiced 5,221  5,019 
Accrued employee related expenses and liabilities 5,225  4,175 
Operating lease obligations 4,641  4,693 
Accrued sales and excise taxes 1,791  2,388 
Accrued interest (2)
1,529  4,106 
Deferred revenue (loyalty program) 1,320  1,407 
Accrued capital expenditures 739  702 
Accrued professional and management fees 398  986 
Acquisition-related milestone accrual (2)
—  4,167 
Contingent consideration liabilities (2)
—  817 
Other accrued expenses and current liabilities 4,765  5,470 
Total accrued expenses and other current liabilities
 $ 35,769  $ 44,070 
(1)Refer to Note 4 - Prepaid Expenses and Other Current Assets for more information.
(2)This amount is related to Sammartino in connection with the acquisition of Nature's Remedy in September 2021. The acquisition-related milestone accrual of $5,000 and accrued interest of $3,030 as of September 30, 2024 was classified as other liabilities - non-current in the consolidated balance sheets, since the Company currently has no obligation to pay these amounts within the next 12 months from the balance sheet date. See further discussion of the Sammartino Matter in Note 16 - Commitments and Contingencies.